Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Blue Earth Therapeutics Ltd
Pathos AI, Inc.
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
K36 Therapeutics, Inc.
Atavistik Bio, Inc
Washington University School of Medicine
Spanish Oncology Genito-Urinary Group
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
RenJi Hospital
Eli Lilly and Company
The Netherlands Cancer Institute
City of Hope Medical Center
Jinling Hospital, China
University of California, San Francisco
NiKang Therapeutics, Inc.
University of Washington
Johns Hopkins University
University of Miami
The Netherlands Cancer Institute
Ottawa Hospital Research Institute
Marengo Therapeutics, Inc.
Lipac Oncology LLC
Eli Lilly and Company
Centre of Postgraduate Medical Education
Advanced Accelerator Applications
Spanish Oncology Genito-Urinary Group
Endocyte
Stanford University
Novartis
UroGen Pharma Ltd.
Algemeen Ziekenhuis Maria Middelares
Poseida Therapeutics, Inc.
Icahn School of Medicine at Mount Sinai
Sharp HealthCare
University Teaching Hospital Hall in Tirol
Regina Elena Cancer Institute
VA Greater Los Angeles Healthcare System
University Health Network, Toronto
Mayo Clinic
Duke University
University Medical Center Groningen
Promontory Therapeutics Inc.
Steba Biotech S.A.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Aragon Pharmaceuticals, Inc.
NanOlogy, LLC